Abstract
Arterial medial calcification (AMC) has been associated with phenotypic changes in vascular smooth muscle cells (VSMCs) that reportedly makes them more osteoblast-like. Previous work has shown that ATP/UTP can inhibit AMC directly via P2 receptors and indirectly by NPP1-mediated hydrolysis to produce the mineralisation inhibitor, pyrophosphate (PPi). This study investigated the role of P2X receptors in the inhibitory effects of extracellular nucleotides on VSMC calcification. We found that Bz-ATP, α,β-meATP and β,γ-meATP inhibited calcification by up to 100%. Culture in a high-phosphate medium (2mM) was associated with increased VSMC death and apoptosis; treatment with Bz-ATP, α,β-meATP and β,γ-meATP reduced apoptosis to levels seen in non-calcifying cells. Calcification was also associated with alterations in the protein levels of VSMC (e.g. SM22α and SMA) and osteoblast-associated (e.g. Runx2 and osteopontin) markers; Bz-ATP, α,β-meATP and β,γ-meATP attenuated these changes in protein expression. Long-term culture with Bz-ATP, α,β-meATP and β,γ-meATP resulted in lower extracellular ATP levels and an increased rate of ATP breakdown. P2X receptor antagonists failed to prevent the inhibitory effects of these analogues suggesting that they act via P2X receptor-independent mechanisms. In agreement, the breakdown products of α,β-meATP and β,γ-meATP (α,β-meADP and methylene diphosphonate, respectively) also dose-dependently inhibited VSMC calcification. Furthermore, the actions of Bz-ATP, α,β-meATP and β,γ-meATP were unchanged in VSMCs isolated from NPP1-knockout mice, suggesting that the functional effects of these compounds do not involve NPP1-mediated generation of PPi. Together, these results indicate that the inhibitory effects of ATP analogues on VSMC calcification and apoptosis in vitro may be mediated, at least in part, by mechanisms that are independent of purinergic signalling and PPi.
Highlights
Vascular calcification is a frequent consequence of chronic kidney disease, diabetes, atherosclerosis and ageing
We recently reported that the inhibitory effects of ATP/UTP on Arterial medial calcification (AMC) are attenuated in Vascular smooth muscle cells (VSMCs) derived from NPP1-knockout mice [6]
Bz-ATP (100 μM) and α,β-meATP (≥ 25 μM) inhibited VSMC calcification by up to 95% (Fig. 2a, b). β,γ-meATP was the most potent of the ATP analogues tested as it completely prevented all calcification at concentrations of ≥ 10 μM (Fig. 2c)
Summary
Vascular calcification is a frequent consequence of chronic kidney disease, diabetes, atherosclerosis and ageing. It is the pathological deposition of calcium phosphate mineral, London, London, UK 5 The Roslin Institute and Royal (Dick) School of Veterinary Studies, University of Edinburgh, Edinburgh, UK typically as hydroxyapatite, in the intimal and/or medial layers of the arteries and heart valves. Vascular smooth muscle cells (VSMCs) are the major cell type driving AMC, and when maintained in a calcifying environment (high calcium and/or phosphate), these cells undergo phenotypic changes to take on some limited osteoblast-like characteristics [3,4,5,6,7]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.